Myology research highlights
RSS feedEarly molecular defects linked to facio-scapulo-humeral dystrophy?
Facio-scapulo-humeral dystrophy (FSHD) results from deletions in the subtelomeric macrosatellite D4Z4 array on the 4q35 region. Upregulation of the DUX4 retrogene from the last D4Z4 repeated unit is thought to underlie FSHD pathophysiology. However, what triggers muscle defect and when alteration arises remains obscure. To gain further insights into the molecular mechanisms of the disease, … [Read more]
Long-term perspective data in favour of corticosteroid therapy for the prevention of scoliosis in DMD
Duchenne muscular dystrophy, a progressive muscle disorder that occurs in males, causes a gradual decline in muscle strength. This progressive decline is associated with the development of scoliosis. Previous studies have shown that the use of glucocorticoids slows the progression of scoliosis, but it is unknown if the spine remains straight in the long term. … [Read more]
Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-in
Duchenne muscular dystrophy (DMD) is a severe inherited, muscle wasting disorder caused by mutations in the DMD gene. Gene therapy development for DMD has concentrated on vector-based DMD minigene transfer, cell-based gene therapy using genetically modified adult muscle stem cells or healthy wild-type donor cells, and antisense oligonucleotide-induced exon skipping therapy to restore the reading … [Read more]
Effect of pre-existing T-cell immunity on the success of therapeutic approaches for restoring dystrophin
Duchenne muscular dystrophy (DMD) typically occurs due to truncating mutations in the DMD gene that result in a lack of expression of the dystrophin protein in muscle fibers. A variety of therapies under development are directed toward restoring dystrophin expression at the subsarcolemmal membrane, including gene transfer. In a trial of intramuscular AAV-mediated delivery of … [Read more]
Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation
Salbutamol is a selective B2-adrenergic agonist, which has previously been described to be associated with partial improvement of myasthenia gravis and congenital myasthenic syndromes (CMS). In this study, the effect of salbutamol in five patients with Dok-7 CMS was analysed. Five patients (2 males and 3 females), with a mean age of 27±11.06years, who harboured … [Read more]
AAV-mediated gene replacement therapy for FKRP-related muscular dystrophies
Mutations in FKRP gene are associated with a wide range of muscular dystrophies from mild limb-girdle muscular dystrophy (LGMD) 2I to severe Walker-Warburg syndrome (WWS) and muscle-eye-brain disease (MEB). The characteristic biochemical feature of these diseases is the hypoglycosylation of α-dystroglycan (α-DG). Currently there is no effective treatment available. In this study the Adeno-associated virus … [Read more]
GMPPB mutations cause muscular dystrophy variants with hypoglycosylated á-DG
Congenital muscular dystrophies with hypoglycosylation of α-dystroglycan (α-DG) are a heterogeneous group of disorders often associated with brain and eye defects in addition to muscular dystrophy. Causative variants in 14 genes thought to be involved in the glycosylation of α-DG have been identified thus far. Allelic mutations in these genes might also cause milder limb-girdle … [Read more]
SET binding factor 1 (SBF1) mutations cause Charcot-Marie-Tooth disease type 4B3
In this study, the authors aimed to identify the genetic cause of an autosomal recessive demyelinating Charcot-Marie-Tooth disease type 4B (CMT4B) family in 14 members of a Korean family. Three individuals had demyelinating CMT4B phenotype and obtained distal sural nerve biopsies from all affected participants. Exome sequencing was performed on 6 samples (3 affected and … [Read more]
A prospective study of patients with non-dystrophic myotonia
Non-dystrophic myotonias are rare diseases caused by mutations in skeletal muscle chloride and sodium ion channels with considerable phenotypic overlap between diseases. Few prospective studies have evaluated the sensitivity of symptoms and signs of myotonia in a large cohort of patients. In this study, the authors performed a prospective observational study of 95 participants with … [Read more]
Antisense oligonucleotides as personalised medicine for Duchenne muscular dystrophy
DMD is a severe X linked neuromuscular disorder where symptoms may arise as early as 2 years of age and patient surviving till adulthood is extremely rare. This is caused by mutations in dystrophin-a critical gene for muscle fibre strength- leading to a severe reduction of the dystrophin protein in muscles. A milder form DMD … [Read more]